Business Context and Reporting Period
This Form 8-K Current Report was filed by West Pharmaceutical Services, Inc. on September 11, 2025. The filing reports a significant executive departure rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statement data.
Material Changes
The primary material change reported is the departure of Kimberly Banks MacKay, who served as Senior Vice President, General Counsel, and Corporate Secretary. She will remain with the company through a transition period ending no later than December 31, 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. Management commentary is limited to expressing gratitude for Ms. MacKay's service and confirming that she will continue her current duties to ensure a smooth transition of responsibilities.
Investor Verification Checklist
- Verify the appointment of a successor for the roles of General Counsel and Corporate Secretary.
- Confirm the exact end date of the transition period, which is stated as no later than December 31, 2025.
- Review subsequent filings for any impact on legal or corporate governance functions during the transition.